Top View
- Romidepsin in the Treatment of Hematologic Malignancies
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory
- Patient-Assistance-Reimbursement-Guide-2019.Pdf
- Vorinostat Combined with Dnmti Epigenetically Controls the Proliferation of Lung Cancer Cells A549
- Emerging Drugs for Prostate Cancer
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
- Phase I/II Intra-Patient Dose Escalation Study of Vorinostat in Children with Relapsed Solid Tumor, Lymphoma, Or Leukemia Cornelis M
- Phase 1/1B Pembrolizumab Plus Vorinostat in Advanced NSCLC
- The Inhibitor of Histone Deacetylases Sodium Butyrate Enhances the Cytotoxicity of Mitomycin C
- Low Concentrations of Vorinostat Decrease EB1 Expression in GBM Cells and Affect Microtubule Dynamics, Cell Survival and Migration
- HDAC Inhibitors: Dissecting Mechanisms of Action to Counter Tumor Heterogeneity
- Zolinza (Vorinostat) Usage in the Treatment of Cancer, Including FDA Approved Indications, and Off-Label Indications
- Nanofiber-Coated Stent for Inhibition of Cholangiocarcinoma Cells
- The Histone Deacetylase Inhibitor Vorinostat Induces Calreticulin
- Targeting HDAC with a Novel Inhibitor Effectively Reverses Paclitaxel Resistance in Non-Small Cell Lung Cancer Via Multiple Mechanisms
- Histone Deacetylase Inhibitor Induces DNA Damage, Which Normal but Not Transformed Cells Can Repair
- Strategies to Circumvent the T315I Gatekeeper Mutation in the Bcr-Abl Tyrosine Kinase
- Early Stage Treatment Options Theresa Pacheco, Md
- Clinicaltrials.Gov Record Including Results
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone DNAJA1
- Novel Therapies for Relapsed and Refractory Neuroblastoma
- Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-Hdacis) in the Treatment of Solid Malignancies
- Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma
- ECP for CTCL
- Romidepsin for Cutaneous T-Cell Lymphoma
- Risk Assessment and Risk Mitigation Review(S)
- Vorinostat, a Histone Deacetylase Inhibitor, Enhances the Response of Human Tumor Cells to Ionizing Radiation Through Prolongation of ;-H2AX Foci
- Randomized Trial of Intermediate-Dose Cytarabine In
- Cancer Drug Costs for a Month of Treatment at Initial Food and Drug
- Current Management Approaches of Chronic Myeloid Leukemia
- Characteristics of Non-Randomized Studies Using Comparisons with External Controls Submitted for Regulatory Approval in the Us and Europe: a Systematic Review
- ZOLINZA (Vorinostat) Capsules Should Not Be Opened Or Crushed
- FDA Approval: Belinostat for the Treatment of Patients with Relapsed Or Refractory Peripheral T-Cell Lymphoma Hyon-Zu Lee1, Virginia E
- Vorinostat (Zolinza)
- Solubilization of Panobinostat with Cyclodextrins for Anticancer Therapies 1 Multiple Myeloma
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- Do Not Tube List
- A Novel Pan-Deacetylase Inhibitor with Activity in T Cell Lymphoma
- Safety and Preliminary Efficacy of Vorinostat with R-EPOCH in High-Risk HIV-Associated Non-Hodgkin's Lymphoma (AMC-075)." Clinical Lymphoma Myeloma and Leukemia.18,3
- Vorinostat, a Pan-HDAC Inhibitor, Abrogates Productive HPV-18 DNA Amplification
- (Hdacis) in OVARIAN CANCER
- Open Full Page
- Biomedicines
- Vorinostat, Temodar & RT for Newly Diagnosed GBM CC827/ABTC 0902
- Phase I Study of Decitabine in Combination with Vorinostat in Patients with Advanced Solid Tumors and Non-Hodgkin's Lymphomas
- Hazardous Drug List
- WITHDRAWAL ASSESSMENT REPORT for Vorinostat MSD 100 Mg Hard Capsules
- Histone Deacetylase Inhibitors: Molecular Mechanisms of Action
- Role of Checkpoint Kinase 1 (Chk1) in the Mechanisms of Resistance to Histone Deacetylase Inhibitors
- Histone Deacetylase Inhibition with Panobinostat Combined with Intensive Induction
- The Histone Deacetylase Inhibitor Panobinostat Is a Potent Antitumor Agent in Canine Diffuse Large B-Cell Lymphoma